Eaglenos Sciences
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Preclinical oncology biotech developing novel small molecule targeted therapies.
Oncology
Technology Platform
Integrated drug discovery platform utilizing structure-based design and translational cancer models to develop selective small molecule inhibitors.
Opportunities
Potential to discover a novel best-in-class therapy for a high-value oncology target with significant commercial upside.
Risk Factors
High risk of preclinical failure and difficulty in securing follow-on funding in a competitive investment climate.
Competitive Landscape
Operates in the extremely crowded early-stage oncology space, requiring exceptional data to stand out to investors and potential partners.